8 Reasons Why Medtronic is a Great Investment OptionMedtronic is a medical device company that focuses on research, development, manufacturing, and distribution of various medical devices. The company has grown rapidly in the last few years thanks to its strong performance and focus on innovation. In this article, we will discuss why Medtronic remains a strong investment option with a promising future ahead.
Reasons to invest in Medtronic
The strong financial position of Medtronic is one of the main reasons to invest in it. The company’s debt-to-equity ratio is below 1.0, which means that its debt is well below its equity base. This is an important ratio to watch as an investor, especially if the company is heavy on debt – as that indicates that the company may run into trouble in the future especially in times like these where interest rates are going up. The company’s return on equity (ROE) is consistently above its cost of equity, which means that it is earning much more than its shareholders could expect in a risk-free investment. Similarly, Medtronic’s debt-to-asset ratio is below 40%, which shows that its debt is lower than its assets. This is important to look at when evaluating a company’s financial position, as it indicates the company is mostly likely to be able to pay back its debt even in a worst-case scenario.
Strong Financial Position
Another factor to consider when evaluating a company’s financial position is its liquidity. Liquidity is the ability of a company to quickly turn its assets into cash if needed. When it comes to Medtronic, the company has enough liquidity thanks to its cash on hand, cash from operations, and other short-term investments that can easily be turned into cash. Similarly, Medtronic’s current ratio (the number of current assets compared to current liabilities) is above 1.0, which indicates that the company has enough current assets to meet its current liabilities. This ratio is important to look at because it indicates whether or not a company can meet its short-term obligations while also pursuing long-term goals.
Strong Track Record of Growth Through Acquisitions
Medtronic has a strong track record of growth through acquisitions, having acquired dozens of companies in its history. This is important to watch out for when investing in a company – especially if it has a history of poor acquisitions. This can lead to lost capital for investors as well as a company that is unfocused. However, the acquisitions Medtronic has made have all been successful and focused around the company’s core business. This has allowed Medtronic to offer a wide range of products around the world while also keeping its R&D focused on the most important innovations.
Integration of CareLink with Guardian 2 platform
Another example of a successful acquisition is when Medtronic purchased CareLink in 2015 for $250 million. CareLink is a company focused on creating remote patient monitoring solutions that are designed to help patients manage chronic diseases at home. Following the acquisition, CareLink was integrated into Medtronic’s Guardian 2 remote care platform, which connects patients and doctors while also allowing patients to monitor their own health. This represents a huge opportunity for Medtronic as it expands its remote monitoring capabilities. This is especially relevant as more and more people are living with chronic conditions that require consistent monitoring. This is expected to lead to a huge opportunity for remote monitoring solutions in the future.
Solid Return on Investment for Medtronic Investors
When looking at the company’s return on investment (ROI), it is important to note that this is a long-term number. This means that you want to see a high ROI, but this number is not as important as a company’s short-term numbers. However, when it comes to investment, the long-term numbers are actually more important than the short-term numbers. The short-term numbers are important because they indicate how strong of a short-term investment a company is. The long-term numbers are important because they show the potential for long-term growth.
Solid Base of Popular Brands/Products for Medtronic
Another important factor to look at when evaluating Medtronic is its core products and brands. These are the products and brands that define Medtronic as a company, and they are what has helped the company grow over the last few decades. These products/brands can give us insight into Medtronic’s future plans, because the company has to consistently update and improve these products to meet consumer demand.
Medtronic is venturing into the artificial intelligence space
One of the biggest trends in the medical device industry is the adoption of artificial intelligence (AI). AI can be used to help medical devices better understand their environment and collect data/information on patients while also allowing them to communicate with other devices. This can be extremely helpful in the medical device industry, especially when it comes to remote monitoring solutions – which is an area in which Medtronic is already growing. One of Medtronic’s key acquisitions in recent years was HealthMine, which is a company focused on the AI space within medical devices. This acquisition could allow Medtronic to significantly expand its AI capabilities and help the company keep up with the latest trends in its industry.
Financials
EPS
Dividend Yield %
Valuation Metrics
Summing up
There are many reasons why Medtronic is a great investment option. The company has a strong financial position, a strong track record of growth through acquisitions, an integration of its CareLink acquisition with its Guardian 2 platform, a solid base of popular brands/products for Medtronic, and Medtronic is venturing into the artificial intelligence space. These are all reasons to invest in Medtronic because they show a strong future ahead.
Healthcare
AHPI | Under-valued PlayAllied Healthcare Products, Inc. manufactures and markets respiratory products for use in the health care industry in a range of hospitals and alternate site settings worldwide. The company offers respiratory care/anesthesia products, including air compressors, calibration equipment, humidifiers, croup tents, and equipment dryers, as well as respiratory disposable products, such as oxygen tubing products, facemasks, cannulas, and ventilator circuits; and home respiratory care products comprising aluminum oxygen cylinders, oxygen regulators, pneumatic nebulizers, portable suction equipment, and a line of respiratory disposable products. It also provides medical gas equipment, which include construction products consisting of in-wall medical system components, central station pumps and compressors, and headwalls; regulation devices and suction equipment comprising flowmeters, vacuum regulators, and pressure regulators, as well as related adapters, fittings, and hoses that measure, regulate, monitor, and transfer medical gases from walled piping or equipment to patients; and disposable oxygen cylinders to provide oxygen for short periods. In addition, the company offers emergency medical products that include respiratory/resuscitation products, such as demand resuscitation valves, portable resuscitation systems, bag masks and related products, emergency transport ventilators, precision oxygen regulators, minilators, multilators, and humidifiers; and trauma and patient handling products that include spine immobilization products, pneumatic anti-shock garments, and trauma burn kits. It serves hospitals, hospital equipment dealers, hospital construction contractors, home health care dealers, emergency medical products dealers, and others. The company was incorporated in 1979 and is headquartered in St. Louis, Missouri.
HCAT Technical trade THIS IS NOT ADVICEThis ticker looks to be expanding its name with recent acquisitions, but the real reason for the trade is technical in nature, with clear momentum to the upside, horizontal resistance levels being turned to support, bullish divergence on the longer time frame, technicals are setup to look for a return to previous levels off the backs of a strong Bulldiv rally from oversold levels, setting a stop below the recent swing low allows for a technical trade plan that removes emotion. The slightly impressive R/R lines up with the bottom of the recent march low making it conservative, too. if the position is large enough, it could be managed through selling calls and use the premiums to hedge against a drop, just close out any short calls before dumping shares and make sure any short calls are initially sold with a strike above entry. AS ALWAYS!! make sure that any calls sold are done so with a full understanding of any possible dividend liabilities or obligations.
NOT ADVICE, SIMPLY FOR FUN AND THEORY
Veeva SystemsThis is a daily chart of Veeva Systems (VEEV), a healthcare technology company that provides cloud solutions for the global life sciences industry.
When the company reported its earnings on August 31st the stock price subsequently gapped down, as shown in the chart above. From a probability standpoint, this gap is likely to be filled for the reasons below.
1. The gap is a monthly candle gap and these usually close.
Unfilled gaps on the monthly charts are generally quite rare, especially for assets that have never left a monthly gap before. As shown in the chart below, VEEV has never left a gap on its monthly chart before.
2. The gap is below the lower regression channel line. A regression channel is used to measure how far above or below an asset is trading from its mean. Since price generally tends to mean revert, it's highly unlikely that a gap below the lower channel line, (which in this case represents two standard deviations below the mean), will never be filled. It's more likely that the gap will not only be filled, but will be filled quite rapidly. The assumption I make in using this regression channel is that it is statistically valid and data are normally distributed. If true, then there's only a small probability that VEEV's monthly candle will close the month so far below the lower line of the regression channel. Therefore, it's likely that price will be drawn back up to the mean, and thus the gap will be filled.
Here's a close up view:
3. Price gapped below an important Fibonacci level that has been holding, and likely will continue to hold, as support. See the chart below.
Here are some close up views:
At a minimum, price will very likely push back into the 180s.
The quarterly chart shows long lower wicks at this Fibonacci level, indicating that it is holding as support. With further momentum to the downside waning as shown by the Stochastic RSI, there's little reason to believe this Fibonacci level will fail this time.
The lower wicks on the quarterly candles are also bouncing off of the exponential moving average (EMA) ribbon, which usually acts as support when price descends to it from above.
Strategy
With this said, I noticed that someone is already sweeping the call options. They swept hundreds of out-of-the-money (OTM) call options expiring on 9/16 with a $180 strike. Clearly, this buyer believes that VEEV's price is poised to quickly return at least to the Fibonacci support level of $180.97.
If you don't know what an options sweep is, it simply refers to an instance in which options are purchased right at the ask price. In most cases, buyers place a limit buy at the mid point of the bid-ask spread or at a lower target price. Market participants usually only buy at the ask price if they're in a rush to buy and/or if they have a high confidence about a certain market move and want to guarantee their entry while also not tipping the market off about their anticipated market move. Sweeps can also refer to when a large buyer wants to obfuscate their entry by splitting their large order into a lot of smaller parts to sweep the entire order book without tipping off the market as they would have if they placed a single large limit order. Understanding sweeps can help you understand what smart money is doing. It's very rare that retail traders sweep the order book because it's very expensive, and for a smaller portfolio (less than a million) it can be extremely risky. Therefore, smart money is usually the market participant who sweeps the order book.
Personally, I find this call sweep to be risky (assuming that it's not part of some kind of a hedge) since although we have a high confidence that the gap may close, we don't know within what time frame it will do so. Rather than sweeping a call option with a strike price of $180 that expires on 9/16 a safer though less lucrative trade would be to sell a cash-secured put with a strike price of $180 and which expires on 9/16. Doing this gives you much higher odds of winning but is profit limited.
If the price goes to $180 or higher at expiration, you win the full premium since the put you sold will not be exercised.
If the price is below $180 but above the breakeven price at expiration, or if the price is below even your breakeven price, then you may be forced to buy shares of VEEV at $180, but you can simply hold those shares until the gap closes (or longer if you think price is going higher). Therefore in this case you still do not lose money, and still make the premium as profit.
The only plausible scenario whereby you would lose money would be if VEEV's price continued to plummet and never recovers. Although this would be incredibly unlikely, it is still possible. You can nonetheless still hedge against even this risk by using a put spread to limit loss potential to a ratio that meets your risk management strategy. Therefore you can safely take a very high probability trade while managing risks well. Successful trading is mostly determined by how well you manage risks.
Finally, since options are leveraged, one should always try to time their entry as perfectly as possible by using shorter timeframe (hourly or 4-hour) charts, especially if the option's expiration is close. For example, you can see that the 4 hour chart for VEEV is showing momentum building back to the upside. This is what you want to see if you're going to sell a put option strategy that expires on 9/16.
These are just my thoughts and they are definitely not meant to be trading advice. As always, anything can happen. September can often be a volatile month and is prone to declines. Options trading is risky and can result in complete loss. Trade at your own risk.
If you would like me to post more strategies like this on here leave a boost or a comment below so I can gauge interest. Thank you.
If you're new to trading and don't understand the options trading language that I used above, I would recommend Project Finance to learn about options. I learned a ton about options trading from this channel and the content is always high-quality: www.youtube.com
If you want to learn more about the basics of trading, you can see my post linked below for 10 rules for successful trading.
Roche Holding AG bullish scenario:The technical figure Triangle can be found in the daily chart in the German company F. Hoffmann-La Roche AG (ROG.vx). Roche is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. Roche is the fifth largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. The Triangle broke through the resistance line on 07/09/2022, if the price holds above this level, you can have a possible bullish price movement with a forecast for the next 10 days towards 333.65 CHF. Your stop-loss order, according to experts, should be placed at 311.75 CHF if you decide to enter this position.
Roche announced the launch of the Digital LightCycler System, Roche’s first digital polymerase chain reaction (PCR) system. This next-generation system detects disease and is designed to accurately quantify trace amounts of specific DNA and RNA targets not typically detectable by conventional PCR methods.
The Digital LightCycler System will allow clinical researchers to divide DNA and RNA from an already extracted clinical sample into as many as 100,000 microscopic individual reactions. The system can then perform PCR and produce highly sophisticated data analysis on the results.
Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
$AMLX, following the Bio TechsThe health care industry is being leading the charge, NASDAQ:AMLX is the proof of that. This recent IPO just broke out of a good looking cup & handle pattern. Also, IBD is giving a 99 relative strength rating.
So, I enter today with a small position. A "pilot position", as Mark Minervini would say. The market is still under pressure so I'm testing it.
As this stock is a highly volatile I'll play for a 3:1 risk/reward.
Malaysia Health Care Index. Elliottwave updated 17/ August/22Malaysia Health Care index which comprised mostly from Gloves / Pharmaceutical stocks may “found” its “bottom” as price near its major weekly demand Zone.
Pharma. Elliott waves updated 17/ August /22Pharma. As Malaysia Health Care Index which comprised mostly Pharmaceutical and Gloves stocks most likely found its “bottom”. While Malaysia Health Care Index found its bottom but not its KLCI index any reasons why?...
P&G BreakoutThe stock has broken out and retested, therefore may undergo a reversal rally. Trade is supported by Supports Nearby.
Risk Reward Ratio - 2:1
SL is placed below the support zone & the lower trendline. The target is placed near resistance.
Healthcare leader $PRGO making a shark pattern Perrigo is in the Medical-Generic Drugs Group, they develop, manufactures, markets, and distributes private label self-care products, including cough, cold, and allergy products, analgesics, gastrointestinal products, smoking cessation products, infant formula and food products.
IBD gives it a #1 rank in its industry.
PRGO made its major low in May while XLV made it in late June. That's very good relative strength. Now, after the price broke above its 200-day MA, its been forming a base giving a good opportunity to buy.
The price is making shark pattern with a pivot buy at $43.01. I'll leave a STOP BUY at that level.
$VEEV sold covered call 240 $VEEV - everything goes according to plan. We crossed the 200SMA, we might retest back there. There's a huge supply zone around $227-$240 where the stock is struggling today. I own shares and sold covered calls for August 19, 240 strike.
$MASS, growth stock close to breakout908 Devices Inc is in the Medical-Research Eqp/Svc Group. It develops analytical devices for chemical and biomoecular solutions.
The price made a shortfall within the channel that has been forming since January. This shortfall may signal a breakout in the right direction.
I would buy it with a target sell at its next resistance level which is at $29, that's a +20% profit. Play this trade with your own risk/reward strategy. I'm sure I will.
Also just recently, the company tweeted: "Proud to share our #MX908 device was chosen by the U.S. Army to provide chemical identification in their #AugmentedReality training program, ensuring optimal safety when encountering unidentified substances".
3M Company (MMM) bullish scenario:The technical figure Falling Wedge can be found in the daily chart in the US company 3M Company (MMM). The 3M Company is an American multinational conglomerate corporation operating in the fields of industry, worker safety, U.S. health care, and consumer goods. The company produces over 60,000 products under several brands, including adhesives, abrasives, laminates, passive fire protection, personal protective equipment, window films, paint protection films, dental and orthodontic products, electrical and electronic connecting and insulating materials, medical products, car-care products,electronic circuits, healthcare software and optical films. The Falling Wedge has broken through the resistance line on 27/07/2022, if the price holds above this level, you can have a possible bullish price movement with a forecast for the next 27 days towards 155.52 USD. Your stop-loss order, according to experts, should be placed at 125.60 USD if you decide to enter this position.
3M Co. said it would spin off its healthcare business as a public company and sought bankruptcy protection for a subsidiary that once produced military earplugs that thousands of veterans now blame for damaging their hearing.
The moves Tuesday attempt to address the industrial conglomerate’s lingering overhangs with sluggish growth of its businesses and an increasing exposure to costs for lawsuits.
The company said it has committed $1 billion to fund a trust to pay claims about its earplugs and $240 million to fund expected expenses related to the cases. 3M said it would provide more funding if required. The company filed for bankruptcy for Aearo Technologies, a subsidiary that once made the earplugs, as a way to fence off the litigation from the rest of 3M.
Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
$VEEV looks good VEEV looks good. Above 10,20,50 and 100 MA. 200SMA standing in the way around $234. Nice uptrend for now. Stock is strong.
The health care sector ($XLV) is looking bullish!Notes:
* It seems like the health care sector is making an inverse head and shoulders pattern.
* A break out from this pattern could mean that health care stocks lead the market and the sector may see new all-time-highs.
* Be on the lookout for trade ideas in this sector as it's showing tonnes of accumulation recently
* You may also look to buy the sector ETF if it makes a daily close above the white trend line with higher than average volume.
ABBV LONGGood volume push from lows and then sideways action on low volume, looks really good for a breakout above 154
JUL 22 155C can work
ISRG ascending triangleForming an Ascending triangle. I like how 50DMA and top of ascending triangle coinciding at the same place. These type of setups tend to be really powerful when they break. Jul 22 220C can work on breakout.
SWAV looks really goodFundamentally really good company breaking down trend line in a strong sector. Options chain is pretty trash on it but can be a shares play.
Green in the sea of red: Biotech (2)Summary
This week we are sharing 2 rebound trade opportunities in healthcare and biotech, AMEX:XLV and AMEX:XBI , which are showing relative strength against S&P500 and Nasdaq , making them better candidates to trade for rebound.
Since the beginning of 2022, skyrocketing inflation and increasing recession risk have pushed the broad equity markets to the downside. S&P500 is down more than 20% from peak, while the more tech heavy Nasdaq is down close to 30% from peak as of today. If we look back the whole rally, it all started during Mar-2020 as the Fed reacted aggressively toward covid by massive money printing (i.e. quantitative easing). In fact both S&P500 and Nasdaq are now getting closer to the 250 weeks moving average, which is approximately where the post-covid rally had broken the pre-covid peak. Rebound is very likely to happen as “where it started” is usually a strong resistance level that slows correction.
S&P500
Nasdaq100
To execute this trade, instead of directly longing the indexes, healthcare and biotech sector ETF, AMEX:XLV and AMEX:XBI are showing relative strength against S&P500 and Nasdaq100, which make them better candidates to trade the idea. Fundamentally speaking, we believe the reason behind the strength is due to the irreversible trends of aging population across the globe especially among developed countries; as well as in the seemingly more frequent pandemic outbreaks during recent years. Both trends create steady demand for healthcare and need for biotechnological innovation. The MRNA technology is a good recent example to illustrate the importance of biotechnological innovation in fighting pandemic.
We recommend more conservative traders to execute the idea with AMEX:XLV (link here: ), while more aggressive traders can go with AMEX:XBI (this post) which is relatively volatile.
Note : XBI also come with 3X leveraged ETF AMEX:LABU (bullish) and AMEX:LABD (bearish) for those who are looking for more leverage with same amount of capital
Technical
The 250 days moving average of AMEX:XBI is pointing downward, and it is currently trading below the 250 days moving average, which confirms the down trend is still effective for AMEX:XBI . Benchmarking with NASDAQ:QQQ (Nasdaq100 index ETF), although both are in similar down trend, AMEX:XBI 20 days moving average has already crossed the 50 days moving average while that of NASDAQ:QQQ still running below, which shows stronger confirmation of the rebound for AMEX:XBI than NASDAQ:QQQ .
Here are some important level one should pay attentions to:
Downside support
72.55: Jun-30 retest low after breaking 50 days moving average
61.78: May-12 52 weeks low
Upside resistance
84.63: Jul-8 high after breaking 50 days moving average
97.19: Apr-5 high before creating new low on May-12
118.23: 2021 May-10 consolidation bottom, which was broken, retested and continued to the downside during 2021 Nov to Dec
Green in the sea of red: Healthcare (1)Summary
This week we are sharing 2 rebound trade opportunities in healthcare and biotech, AMEX:XLV and AMEX:XBI , which are showing relative strength against S&P500 and Nasdaq , making them better candidates to trade for rebound.
Since the beginning of 2022, skyrocketing inflation and increasing recession risk have pushed the broad equity markets to the downside. S&P500 is down more than 20% from peak, while the more tech heavy Nasdaq is down close to 30% from peak as of today. If we look back the whole rally, it all started during Mar-2020 as the Fed reacted aggressively toward covid by massive money printing (i.e. quantitative easing). In fact both S&P500 and Nasdaq are now getting closer to the 250 weeks moving average, which is approximately where the post-covid rally had broken the pre-covid peak. Rebound is very likely to happen as “where it started” is usually a strong resistance level that slows correction.
S&P500
Nasdaq100
To execute this trade, instead of directly longing the indexes, healthcare and biotech sector ETF, AMEX:XLV and AMEX:XBI are showing relative strength against S&P500 and Nasdaq100, which make them better candidates to trade the idea. Fundamentally speaking, we believe the reason behind the strength is due to the irreversible trends of aging population across the globe especially among developed countries; as well as in the seemingly more frequent pandemic outbreaks during recent years. Both trends create steady demand for healthcare and need for biotechnological innovation. The MRNA technology is a good recent example to illustrate the importance of biotechnological innovation in fighting pandemic.
We recommend more conservative traders to execute the idea with AMEX:XLV (this post), while more aggressive traders can go with AMEX:XBI (link here: ) which is relatively volatile.
Note : XBI also come with 3X leveraged ETF AMEX:LABU (bullish) and AMEX:LABD (bearish) for those who are looking for more leverage with same amount of capital
Technical
AMEX:XLV is still outperforming major indexes. Instead of downtrend, AMEX:XLV is still in a consolidation period. AMEX:XLV has been trading in extending box range since Oct-2021, with 1 extension to the upside in Dec-2021, and 1 extension to the downside this year on Jun-13.
The more than 8 months of consolidation period has flattened the 250 days moving average, yet not bending it downward (yet?). 20 days and 50 days moving averages have been crossing each other multiple times during the consolidation period, making them less indicative from a technical perspective. Currently AMEX:XLV is trading below 250 days moving average, tested but failed to penetrate the moving average on Jul-8, if it still cannot get above the 250 days moving average in the coming months, the downside pressure will materialize into an actual down trend.
In summary, these are the important levels one should pay attention to:
Downside support
118.75: Jun-13 new box bottom
109.74: Post covid peak before rallying to the upside
Upside resistance
132.04: Jul-8 attempt of breaking 250 days moving average
143.42: Apr-8 new box top
7/4/22 SWAVShockWave Medical, Inc. ( NASDAQ:SWAV )
Sector: Health Technology (Medical Specialties)
Market Capitalization: $7.109B
Current Price: $198.62
Breakout price: $200.15
Buy Zone (Top/Bottom Range): $194.30-$180.50
Price Target: $217.20-$221.90 (1st), $246.50-$249.80 (2nd)
Estimated Duration to Target: 38-40d (1st), 83-88d (2nd)
Contract of Interest: $SWAV 8/19/22 195c, $SWAV 10/21/22 195c
Trade price as of publish date: $19.10/contract, $26.50/contract
7/4/22 AMNAMN Healthcare Services Inc. ( NYSE:AMN )
Sector: Commercial Services (Personnel Services)
Market Capitalization: $5.130B
Current Price: $114.73
Breakout price: $115.20
Buy Zone (Top/Bottom Range): $113.95-$108.40
Price Target: $120.90-$123.70
Estimated Duration to Target: 38-40d
Contract of Interest: $AMN 8/19/22 110c
Trade price as of publish date: $10.80/contract
VEEV - uptrendAnother stock that seems to have bottomed. 10, 20, 50 MA curled up, it's a lot above 100 MA and I wouldn't be surprised if we retest around $192 and the 100 MA before we grind higher. Also, the 200MA is pretty far away so we might be moving in this range for a bit but overall, the trend looks better than other tech names.
